Raltegravir
- Generic Name
- Raltegravir
- Brand Names
- Isentress
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN6O5
- CAS Number
- 518048-05-0
- Unique Ingredient Identifier
- 22VKV8053U
- Background
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
- Indication
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Post-exposure prophylaxis for occupational exposure to HIV therapy
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2021-11-08
- Target Recruit Count
- 40
- Registration Number
- NCT01828073
- Locations
- 🇹🇭
Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand
🇺🇸St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States
🇺🇸University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States
Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Dietary Supplement: Ready to Use Supplementary Food
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Anna Griffiths, MRC
- Target Recruit Count
- 1805
- Registration Number
- NCT01825031
- Locations
- 🇺🇬
Joint Clinical Research Centre, Mbale, Mbale, Uganda
🇰🇪Moi University Clinical Research Centre, Eldoret, Kenya
🇰🇪KEMRI Wellcome Trust Research Programme, Kilifi, Kenya
Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT01785160
- Locations
- 🇩🇪
1220.65.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany
The Effect of Antacids and Multivitamins on Raltegravir
- Conditions
- HIV
- Interventions
- Drug: Maalox Plus extraDietary Supplement: MultivitaminsDietary Supplement: Sodium bicarbonate
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Helen Reynolds
- Target Recruit Count
- 15
- Registration Number
- NCT01784302
- Locations
- 🇬🇧
Royal Liverpool University Hospital, Liverpool, United Kingdom
Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 52
- Registration Number
- NCT01780831
- Locations
- 🇿🇦
Umlazi CRS, Durban, KwaZulu-Natal, South Africa
🇹🇭Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand
🇺🇸Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States
Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT01779687
- Locations
- 🇳🇱
CRCN Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 23
- Registration Number
- NCT01767701
- Locations
- 🇬🇧
The Royal London Hospital, London, United Kingdom
Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 40
- Registration Number
- NCT01751568
- Locations
- 🇿🇦
Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa
🇿🇦Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)
- Conditions
- HIV Infection
- Interventions
- Drug: Other Anti-Retroviral Therapy
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01717287
Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study
- Conditions
- Quality of LifeHIV InfectionAdverse Drug Reaction
- Interventions
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- Lin, Hsi-Hsun, M.D.
- Target Recruit Count
- 107
- Registration Number
- NCT01679964
- Locations
- 🇨🇳
Taipei City Hospital, Taipei, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.